FATE THERAPEUTICS INC
Congressional Trades
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
Daniel S. GoldmanHouse · D · NY |
FATEFATE THERAPEUTICS INC · Stock |
Sale $1,001 - $15,000 |
Feb 24, 2023 | Jan 31, 2023 | Filing ↗ |
Whale Activity
- Increased32
- New17
- Held41
- Decreased50
- Closed29
- No prior filing2
| Filer | Shares | Value | Change |
|---|---|---|---|
| Redmile Group, LLC | 12.9M | $30.5M | held |
| BlackRock, Inc. | 7.1M | $16.8M | decreased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5.0M | $11.8M | increased |
| ACADIAN ASSET MANAGEMENT LLC | 4.8M | $11.3M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.5M | $10.7M | increased |
| TWO SIGMA INVESTMENTS, LP | 3.9M | $9.3M | increased |
| JOHNSON & JOHNSON | 3.4M | $8.0M | held |
| RENAISSANCE TECHNOLOGIES LLC | 2.4M | $5.6M | decreased |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 2.4M | $5.6M | increased |
| MILLENNIUM MANAGEMENT LLC | 2.2M | $5.1M | decreased |
| GOLDMAN SACHS GROUP INC | 2.1M | $4.9M | increased |
| Qube Research & Technologies Ltd | 1.7M | $3.9M | increased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Adawi KamalChief Financial Officer | Sale | −6,582 | $2.05 | $14K | Nov 3, 2026 | Form 4 ↗ |
| TAHL CINDYSee Remarks | Sale | −38.8K | $2.46 | $95K | Aug 4, 2026 | Form 4 ↗ |
| Valamehr BahramPresident and CEO · Director | Sale | −43.9K | $2.46 | $108K | Aug 4, 2026 | Form 4 ↗ |
| TAHL CINDYSee Remarks | Sale | −25.6K | $1.88 | $48K | May 20, 2026 | Form 4 ↗ |
| Valamehr BahramPresident and CEO · Director | Sale | −28.9K | $1.88 | $54K | May 20, 2026 | Form 4 ↗ |
| TAHL CINDYSee Remarks | Option exercise | +44.4K | $1.05 | $47K | May 6, 2026 | Form 4 ↗ |
| TAHL CINDYSee Remarks | Option exercise | +122.2K | $1.32 | $161K | May 6, 2026 | Form 4 ↗ |
| EPSTEIN ROBERT SDirector | Option exercise | +25.0K | $1.69 | $42K | May 5, 2026 | Form 4 ↗ |
| RASTETTER WILLIAM HDirector | Option exercise | +25.0K | $1.69 | $42K | May 5, 2026 | Form 4 ↗ |
| Green JeremyDirector · 10% owner | Other | +9.0M | $0.00 | $0 | Apr 20, 2026 | Form 4 ↗ |
| Green JeremyDirector · 10% owner | Other | −9.0M | $0.00 | $0 | Apr 20, 2026 | Form 4 ↗ |
| TAHL CINDYSee Remarks | Grant / award | +100.0K | $0.00 | $0 | Jan 15, 2026 | Form 4 ↗ |
| Adawi KamalChief Financial Officer | Grant / award | +25.0K | $0.00 | $0 | Jan 15, 2026 | Form 4 ↗ |
| Valamehr BahramPresident and CEO · Director | Grant / award | +335.0K | $0.00 | $0 | Jan 15, 2026 | Form 4 ↗ |
| TAHL CINDYSee Remarks | Sale | −10.6K | $1.06 | $11K | Jan 9, 2026 | Form 4 ↗ |
| Valamehr BahramPresident and CEO · Director | Sale | −5,190 | $1.07 | $6K | Jan 9, 2026 | Form 4 ↗ |
| Adawi KamalChief Financial Officer | Grant / award | +75.0K | $0.00 | $0 | Oct 20, 2025 | Form 4 ↗ |
| TAHL CINDYSee Remarks | Sale | −9,037 | $1.06 | $10K | Aug 4, 2025 | Form 4 ↗ |
| Valamehr BahramPresident and CEO · Director | Sale | −14.5K | $1.06 | $15K | Aug 4, 2025 | Form 4 ↗ |
| TAHL CINDYSee Remarks | Grant / award | +70.0K | $0.00 | $0 | Jan 15, 2025 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 3.2M | $8.6M | 0.00% | Jun 30, 2026 |
| VANGUARD STRATEGIC EQUITY FUND VANGUARD HORIZON FUNDS | 3.0M | $8.0M | 0.07% | Jun 30, 2026 |
| BlackRock Advantage Small Cap Core Fund BlackRock Funds | 1.6M | $3.8M | 0.07% | Aug 31, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.1M | $3.1M | 0.00% | Jun 30, 2026 |
| BRUCE FUND Bruce Fund, Inc. | 989.2K | $2.7M | 0.71% | Jun 30, 2026 |
| VANGUARD STRATEGIC SMALL-CAP EQUITY FUND VANGUARD HORIZON FUNDS | 786.8K | $2.1M | 0.07% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 629.8K | $1.7M | 0.02% | Jun 30, 2026 |
| VANGUARD RUSSELL 2000 INDEX FUND VANGUARD SCOTTSDALE FUNDS | 559.3K | $1.6M | 0.01% | May 31, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 1.1M | $1.3M | 0.00% | Apr 30, 2026 |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 513.8K | $1.2M | 0.00% | Aug 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list FATE's shares (CUSIP 31189P102), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
- Redmile Capital Offshore II Master Fund, Ltd.SCHEDULE 13D/A · activist (13D) · 6.4M shares5.0%
Nov 9, 2026 · ↗ - RedCo II Offshore SPV LLCSCHEDULE 13D/A · activist (13D) · 10.1M shares8.1%
Nov 9, 2026 · ↗ - Jeremy C. GreenSCHEDULE 13D/A · activist (13D) · 19.2M shares15.0%
Nov 9, 2026 · ↗ - Redmile Group, LLCSCHEDULE 13D/A · activist (13D) · 19.2M shares15.0%
Nov 9, 2026 · ↗ - BlackRock, Inc.SCHEDULE 13G/A · passive (13G) · 2.2M shares1.9%
Jul 8, 2026 · ↗ - GOLDMAN SACHS & CO. LLCSCHEDULE 13G/A · passive (13G) · 2.3M shares2.0%
Aug 14, 2025 · ↗ - THE GOLDMAN SACHS GROUP, INC.SCHEDULE 13G/A · passive (13G) · 2.3M shares2.0%
Aug 14, 2025 · ↗
Corporate Lobbying
No lobbying filings found naming FATE THERAPEUTICS INC as the client.
Government Contracts
No federal contract awards found for FATE THERAPEUTICS INC.
U.S. Patents
No USPTO patent applications found for FATE THERAPEUTICS INC.
Annual Financials
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $6.6M | $13.6M | $63.5M | $96.3M | $55.8M |
| Operating income | -$147.7M | -$210.3M | -$190.5M | -$308.4M | -$217.0M |
| Net income | -$136.3M | -$186.3M | -$160.9M | -$281.7M | -$212.2M |
| Diluted EPS | -$1.15 | -$1.64 | -$1.64 | -$2.91 | -$2.24 |
| Operating cash flow | -$106.1M | -$122.9M | -$132.3M | -$248.2M | -$162.9M |
| Cash and equivalents | $46.6M | $36.1M | $41.9M | $61.3M | $133.6M |
| Total assets | $318.9M | $440.7M | $506.2M | $705.6M | $921.5M |
| Shareholders' equity | $207.2M | $318.7M | $368.4M | $483.9M | $678.8M |
As FATE THERAPEUTICS INC tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 26, 2026 ↗
Stock Splits
No stock splits in FATE's price history.
Material Events (8-K)
- 8-K · Items 1.01, 1.02, 9.01Material agreement · Termination of agreementNov 5, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsNov 5, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsSep 28, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 13, 2026
EDGAR ↗ - 8-K · Items 5.02, 5.07, 9.01Officer / director change · Shareholder voteJun 15, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsJun 4, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 13, 2026
EDGAR ↗

